For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

It's the first new type of painkiller in 20 years. And it's just a few weeks away from being here in local pharmacies.

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.